Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VentriPoint DiagnosticsVPTDF -0.71% Days Sales Outstanding is 486.67 as of Dec. 2025, which is 106% above its 10-year median of 236.18. The stock has 4 warning signs investors should review. Among 810 Medical Devices & Instruments companies, VentriPoint Diagnostics ranks better than 78.27% on this metric.
The historical rank and industry rank for VentriPoint Diagnostics's Days Sales Outstanding or its related term are showing as below:
VPTDF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.86 Med: 236.18 Max: 327.76
Current: 44.86
During the past 13 years, VentriPoint Diagnostics's highest Days Sales Outstanding was 327.76. The lowest was 44.86. And the median was 236.18.
VPTDF's Days Sales Outstanding is ranked better than 78.27% of 810
companies
in the Medical Devices & Instruments industry
Industry Median: 65.38
vs VPTDF: 44.86
VentriPoint Diagnostics's Days Sales Outstanding
increased
from Dec. 2024 (0.00) to Dec. 2025 (486.67).
VentriPoint Diagnostics (OTCPK:VPTDF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
VentriPoint Diagnostics Days Sales Outstanding Related Terms
VentriPoint Diagnostics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for VentriPoint Diagnostics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VentriPoint Diagnostics Days Sales Outstanding Chart
VPTDF vs ABT, SYK, MDT: Days Sales Outstanding Comparison
For the Medical Devices subindustry, VentriPoint Diagnostics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VentriPoint Diagnostics Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where VentriPoint Diagnostics's Days Sales Outstanding falls into.
VentriPoint Diagnostics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 486.67 mean?
VentriPoint Diagnostics (VPTDF) has a Days Sales Outstanding of 486.67 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on VentriPoint Diagnostics and its competitors. This is 106% above median its historical median of 236.18. Over the past decade, VentriPoint Diagnostics' Days Sales Outstanding has ranged from 44.86 to 327.76. According to the industry distribution chart, VentriPoint Diagnostics ranks #176 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 21.7%.
Is VentriPoint Diagnostics' Days Sales Outstanding too high?
VentriPoint Diagnostics' current Days Sales Outstanding of 486.67 is 106% above median its 10-year median of 236.18. Over the past 10 years, this metric has ranged from a low of 44.86 to a high of 327.76. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.38. VentriPoint Diagnostics' value of 486.67 is 644.4% above this industry median. Based on the distribution chart, VentriPoint Diagnostics ranks #176 out of 810 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does VentriPoint Diagnostics' Days Sales Outstanding compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VentriPoint Diagnostics ranks #176 out of 810 companies for Days Sales Outstanding. This places VentriPoint Diagnostics in the top 22% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 65.38. VentriPoint Diagnostics' value of 486.67 is 644.4% above this benchmark. Historically, VentriPoint Diagnostics' own Days Sales Outstanding has ranged from 44.86 to 327.76 over the past decade. While the company's 10-year median is 236.18 vs. the industry median of 65.38, VentriPoint Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.38, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VentriPoint Diagnostics's current Days Sales Outstanding of 486.67 is 644.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on VentriPoint Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VentriPoint Diagnostics's current Days Sales Outstanding is 486.67, which is 106% above median its own 10-year median of 236.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current Days Sales Outstanding of 486.67. The current Days Sales Outstanding is 486.67, which is 106% above median its 10-year median of 236.18 and 644.4% above the Medical Devices & Instruments industry median of 65.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current Days Sales Outstanding is 486.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VPTDF has been successfully added to your 
